J Gastric Cancer.  2010 Dec;10(4):168-174.

Phenotypic Differences of Gastric Cancer according to the Helicobacter pylori Infection in Korean Patients

• Park DW
• Lee KJ
• Jin SH
• Lee JH
• Min JS
• Park SH
• Yu HJ
• Bang HY
• Lee JI

Abstract

PURPOSE
Infection with Helicobacter pylori is an important risk factor for gastric cancer in humans. We compared the clinicopathologic features of gastric cancer patients based on H. pylori infection.
MATERIALS AND METHODS
We prospectively studied 155 patients who had gastric cancer and underwent gastrectomies in 1 hospital in Korea. We examined H. pylori infections using the rapid urease test (RUT) with gastrectomy specimens and collected clinical and pathologic data.
RESULTS
The number of H. pylori infections based on the RUT was 137 (88%). The H. pylori-negative group was significantly associated with AGC and tumor histology. H. pylori infection was significantly correlated with type I/IIa in EGC and type III/IV/V in AGC. AGC was significantly correlated with larger tumor size, lymphatic invasion, perineural invasion, and H. pylori infection based on univariate and multivariate analyses.
CONCLUSIONS
We report the prevalence of H. pylori based on the RUT in gastric cancer patients. H. pylori infection influences the tumor histology, progression, and growth type of gastric cancer.

Keyword

Helicobacter pylori; Stomach neoplasms; Phenotype

MeSH Terms

Gastrectomy
Helicobacter
Helicobacter pylori
Humans
Korea
Phenotype
Prevalence
Prospective Studies
Risk Factors
Stomach Neoplasms
Urease
Urease

Reference

1. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983. 1:1273–1275.

2. Fox JG, Correa P, Taylor NS, Zavala D, Fontham E, Janney F, et al. Campylobacter pylori-associated gastritis and immune response in a population at increased risk of gastric carcinoma. Am J Gastroenterol. 1989. 84:775–781.

3. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991. 325:1127–1131.

4. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994. 61:1–241.

5. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998. 114:1169–1179.

6. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 2004. 4:688–694.

7. Yamaoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K, Graham DY. Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol. 1999. 37:2274–2279.

8. Houghton J, Wang TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology. 2005. 128:1567–1578.

9. Stoicov C, Saffari R, Cai X, Hasyagar C, Houghton J. Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. Gene. 2004. 341:1–17.

10. Kim SI, Jin SH, Lee JH, Min JS, Bang HY, Lee JY. An alternative method for a rapid urease test using back-table gastric mucosal biopsies from gastrectomy specimen for making the diagnosis of Helicobacter pylori infection on patients with gastric cancer. J Korean Gastric Cancer Assoc. 2009. 9:172–176.

11. AJCC. AJCC Cancer Staging Manual. 2002. 6th ed. New York: Springer.

12. AJCC. AJCC Cancer Staging Manual. 2009. 7th ed. New York: Springer.

13. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001. 49:347–353.

14. Watanabe Y, Kurata JH, Mizuno S, Mukai M, Inokuchi H, Miki K, et al. Helicobacter pylori infection and gastric cancer. A nested case-control study in a rural area of Japan. Dig Dis Sci. 1997. 42:1383–1387.

15. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001. 345:784–789.

16. Shin A, Shin HR, Kang D, Park SK, Kim CS, Yoo KY. A nested case-control study of the association of Helicobacter pylori infection with gastric adenocarcinoma in Korea. Br J Cancer. 2005. 92:1273–1275.

17. Crabtree JE, Wyatt JI, Trejdosiewicz LK, Peichl P, Nichols PH, Ramsay N, et al. Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol. 1994. 47:61–66.

18. Negrini R, Savio A, Appelmelk BJ. Autoantibodies to gastric mucosa in Helicobacter pylori infection. Helicobacter. 1997. 2:Suppl 1. S13–S16.

19. Suzuki H, Hibi T. Oxidative stress in Helicobacter pylori-associated gastroduodenal disease. J Clin Biochem Nutr. 2006. 39:56–63.

20. Parsonnet J, Vandersteen D, Goates J, Sibley RK, Pritikin J, Chang Y. Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas. J Natl Cancer Inst. 1991. 83:640–643.

21. Kim DY, Park YK, Joo JK, Ryu SY, Kim YJ, Kim SK, et al. Clinicopathological characteristics of signet ring cell carcinoma of the stomach. ANZ J Surg. 2004. 74:1060–1064.

22. Tatsuta M, Iishi H, Okuda S, Taniguchi H, Yokota Y. The association of Helicobacter pylori with differentiated-type early gastric cancer. Cancer. 1993. 72:1841–1845.

23. Lee WJ, Lin JT, Lee WC, Shun CT, Hong RL, Cheng AL, et al. Clinicopathologic characteristics of Helicobacter pyloric seropositive gastric adenocarcinomas. J Clin Gastroenterol. 1995. 21:203–207.

24. Meimarakis G, Winter H, Assmann I, Kopp R, Lehn N, Kist M, et al. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006. 7:211–222.